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The interplay of different cell types of origin and distinct oncogenic mutations may determine the tumor subtype.
We have recently found that although both basal and luminal epithelial cells can initiate prostate tumorigenesis, the
latter are more likely to undergo transformation in response to a range of oncogenic events.
The cell of origin for cancer is defined
as a normal tissue cell that is targeted by
oncogenic events and is transformed to
give rise to a tumor. Over the past few
years, there has been increasing evidence
to support a model in which cancer sub-
types with distinct histopathological fea-
tures or patient outcomes may originate
from different cell types of origin within a
given tissue.1 Therefore, because of the
significant implications of understanding
the cell of origin for facilitating patient
stratification and personalized treatment,
identification of the cells of origin for can-
cer has received considerable interest.
In the normal untransformed prostate,
basal cells and luminal cells represent the
two major epithelial cell types. However,
human prostate adenocarcinomas all dis-
play luminal features, and in fact are diag-
nosed on the basis of the absence of basal
cells. Nonetheless, it has been quite con-
troversial whether basal or luminal cells,
or both, represent the cells of origin for
prostate cancer. For example, previous
studies have isolated human prostate basal
or luminal cells followed by their trans-
duction with oncogenes and found that
only the basal population could support
tumor formation in renal grafts in immu-
nodeficient mice, suggesting basal cells as
the cell of origin.2,3
A major caveat of the renal grafting
approach is that cancer initiation and pro-
gression does not occur in the context of a
native tissue environment. To overcome
this limitation, we and others have utilized
genetic lineage tracing and conditional
deletion of the Pten tumor suppressor
gene specifically in basal or luminal cells
of the mouse prostate, and showed that
both basal and luminal cells could serve as
cell types of origin for prostate cancer in
vivo.4-6 Interestingly, tumors originating
from basal cells displayed luminal pheno-
types since transformed basal cells rapidly
differentiated into luminal cells, which
then propagated the luminal features of
prostate cancer. However, despite their
similar end-stage histopathology, luminal-
derived mouse tumors progressed more
rapidly than basal-derived tumors and had
a distinct molecular profile that correlates
with more aggressive phenotypes in
human patients.4
These findings led us to investigate
whether luminal cells might be more sus-
ceptible to oncogenic transformation in
vivo. Furthermore, we were interested in
determining whether different oncogenic
drivers might affect the ability of a given
cell type to serve as a cell of origin. There-
fore, to test which cell type(s) is favored as
the cell of origin for prostate cancer in
response to distinct oncogenic drivers, we
performed comparative lineage tracing of
basal or luminal cells in a diverse range
of genetically engineered mouse models of
prostate cancer.7
Unlike previous cell-of-origin studies
in which oncogenic drivers were intro-
duced specifically into cell types of inter-
est, we took the converse approach of
expressing the oncogenic drivers through-
out the prostate epithelium, followed by
determination of whether the basal or
luminal cells had generated tumor lesions.
For this purpose, we used mouse models
in which tumor formation was driven by
Myc overexpression (Hi-Myc mice), inacti-
vation of the Nkx3–1 and Pten tumor sup-
pressors, inactivation of the Trp53 and
Rb1 pathways by SV40 T antigen
(TRAMP mice), and elevated levels of
androgen and estrogen hormones, all of
which can drive human prostate tumori-
genesis.8 To determine the cell type of ori-
gin in each mouse model, we lineage
marked basal or luminal cells in histologi-
cally normal prostate prior to tumor for-
mation and then investigated whether
marked cell clusters were present in the
tumors that subsequently arose. Notably,
we found that luminal cells were consis-
tently the observed cell of origin in all of
the models tested.
Our results strongly support the notion
that luminal cells are more prone to
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oncogenic transformation than basal cells
and are the favored cell type of origin in
the endogenous prostate tissue environ-
ment. One potential caveat is that the
genetically engineered models used for
our study express oncogenic events
throughout the prostate epithelium, rather
than in a smaller subset of cells. However,
since the oncogenic stimuli indiscrimi-
nately affected both basal and luminal
cells, we could directly compare their sus-
ceptibility to oncogenic transformation in
a controlled manner. Furthermore, the
hormonal carcinogenesis model does not
rely on any genetically engineered onco-
genic event, and provides unequivocal evi-
dence for luminal cells as the preferred cell
of origin. Although our conclusions differ
from those of Witte and colleagues,2 the
experimental data from these studies are
consistent. In particular, when we isolated
the basal cells from our mouse models and
performed renal grafts in immunode-
ficient nude mice, the grafted cells readily
generated prostate tissue with tumor phe-
notypes. Therefore, both normal and
transformed basal cells demonstrate signif-
icant plasticity when removed from their
endogenous tissue environment.4,7
One model to explain our findings uti-
lizes the concept of “cell of mutation” that
was first proposed in studies of the cell of
origin for glioma.9 In this view, basal cells
carrying oncogenic events display plastic-
ity by acquiring progenitor properties in
renal grafts and behave as cells of muta-
tion, generating progeny luminal cells that
are authentic cells of origin. A recent
report showing that prostate cancer can be
derived from basal cells in renal grafts and
then propagated by luminal cells 10 is con-
sistent with this model. In particular, since
the renal graft assay involves generation of
prostate tissue from a small number of dis-
sociated cells, a process analogous to pros-
tate organogenesis, this assay may not
accurately indicate true cell types of ori-
gin, which only reside in the adult prostate
(Fig. 1).
It should be noted that our finding that
luminal cells are favored as cells of origin
in the mouse models examined does not
exclude the possibility that basal cells are
cells of origin for different models or for
distinct tumor subtypes. Previous lineage
tracing studies have shown that adult basal
cells have the capability to initiate cancer
in situ4-6 and may be responsible for a less
malignant subtype of human
prostate cancers.4 This raises
the question of why we did not
observe any tumors with a basal
cell of origin. One possibility is
that such tumors might be
observed in experimental con-
texts using different oncogenic
drivers. Alternatively, another
possibility is that transformed
luminal cells can out-compete
transformed basal cells and their
growth into tumors in a non–
cell-autonomous manner.
In conclusion, our work
complements prior lineage trac-
ing studies, and together with
previous work provides a clearer
understanding of the cell types
of origin for prostate cancer.
While both luminal cells and basal cells
can in principle serve as cells of origin for
prostate cancer, luminal cells are more sus-
ceptible to oncogenic transformation.
Future research aimed at correlating cells
of origin with subtypes of human prostate
cancers may lead to the identification of
novel molecular biomarkers as well as
therapeutic targets.
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